CorCap controversy headed for panel
This article was originally published in The Gray Sheet
Executive Summary
Acorn Cardiovascular's CorCap cardiac support device has the dubious distinction of being one of two devices referred to FDA's Medical Devices Dispute Resolution Panel in 2006 after three years of inactivity from the independent review body. The panel will convene Dec. 15 to review the science behind the company's PMA application for the polyester mesh wrap, intended to provide ventricular support in patients with symptomatic heart failure despite optimal medical management, Acorn's Oct. 17 release indicates. FDA's Circulatory System Devices Panel voted 9-4 against approval in June 2005 (1"The Gray Sheet" June 27, 2005, p. 3). Cardima's request for a hearing on its Revelation Tx ablation microcatheter system was granted in July (2"The Gray Sheet" July 24, 2006, p. 6)...
You may also be interested in...
CDRH Dispute Resolution Panel Set To Meet For First Time In Years
For the first time in over three years, the ombudsman of FDA's device center has referred a company to the Medical Device Dispute Resolution Panel
CorCap Efficacy Data Deemed Scant By Panel; Acorn Vows Not To Lose Heart
Acorn Cardiovascular will work with FDA to address panel concerns with CorCap that arose during a June 22 meeting to review the ventricular support device
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.